fda peptide warning 2025 september FDA - FDAboxedwarning 2025 FDA Peptide Warning 2025 September: Navigating Regulatory Actions and Safety Concerns

NovoFDA The landscape of peptide-based therapeutics and their associated regulatory oversight is rapidly evolving.FDA removes certain peptide bulk drug substances from ... In September 2025, the FDA has issued a series of significant warning letters and taken other regulatory actions, particularly concerning peptide products and GLP-1 receptor agonistsEli Lilly and Company - 716485 - 09/09/2025. These actions highlight a heightened focus on product safety, efficacy, and proper marketing, underscoring the FDA's commitment to protecting public health....September 16, 2025: "Big Pharma says compounded peptides are “unsafe”. Meanwhile, these same companies have FDA warning letters for dirty ...

A key development in September 2025 was the FDA's issuance of warning letters to over 50 companies involved in the compounding of GLP-1 and peptide products. This broad action indicates a widespread concern regarding the manufacturing practices and quality control of these substances. Specifically, Eli Lilly and Company and Novo Nordisk Inc.PureRawz MARCS-CMS 715218 — September 08, 2025, major players in the GLP-1 market, received warning letters on September 9, 2025. These letters addressed issues related to their promotional materials and direct-to-consumer programs, with An FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept. 9, 2025 being a prominent exampleFDA Warning Letter on misbranded and unapproved Drugs. These warning letters often cite the risk of thyroid C-cell tumors, a concern associated with certain GLP-1 receptor agonists like Zepbound.

In addition to direct warning letters, the FDA has implemented proactive measures to curb the influx of potentially unsafe peptide products. On September 05, 2025, the FDA established a "Green List" import alert. This initiative aims to prevent the import of active pharmaceutical ingredients (APIs) with potential quality concerns, including GLP-1 APIs. This measure, coupled with an ImportAlert 66-40 placed on drugs from Chengdu Brilliant Biopharmaceutical Co2025年9月8日—Based on our review, your Tianeptine products are unapproved new drugs introduced or delivered for introduction into interstate commerce in ...., Ltd. on July 9, 2025, demonstrates the FDA's intensified efforts to control the supply chain and prevent the distribution of unapproved or substandard peptide products.2025年9月16日—(RELATED:FDAcracks down on drugs ads, promises to end adequate provision 'loophole', Regulatory Focus10 September 2025)Warningletters The FDA's action on September 16, 2025, to release more than 60 warning and untitled letters further emphasizes the agency's robust enforcement posture.

The FDA's regulatory scrutiny extends to various aspects of peptide products. For instance, Ralph A.Ralph A. DeFronzo, M.D. - 716773 - 09/17/2025 DeFronzo, M.D., and GLP-1 Solution received warning letters on September 17, 2025, and September 9, 2025, respectively, detailing objectionable conditions observed during FDA inspections2025年9月8日—Based on our review, your Tianeptine products are unapproved new drugs introduced or delivered for introduction into interstate commerce in .... Similarly, PureRawz MARCS-CMS was flagged on September 08, 2025, for marketing unapproved new drugs, including Tianeptine products. The FDA's stance on compounded peptides is also evident in their actions against companies like USA Peptide and Empower Pharmacy, which received warning letters in February 2025 and September 18, 2025. This collective action underscores the FDA's concern that "Big Pharma says compounded peptides are 'unsafe'," while simultaneously facing FDA warning letters for their own product quality issues.

Furthermore, the FDA has been actively reviewing and, in some cases, requesting the removal of specific safety warnings from drug labels. For example, the FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, as noted in documents from January 13, 2026, and January 14, 2026, suggesting a re-evaluation of certain adverse event profiles. This contrasts with the FDA's earlier actions, such as the FDAboxedwarning regarding the risk of thyroid C-cell tumors for Zepbound.CDER Warning Letters Jump 50% in FY 2025

The broader context of these actions includes the FDA's recognition of the growing use of unapproved peptides by Americans2025年9月16日—An FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept. 9, 2025has been made public, regarding a direct-to-consumer program .... The FDA's efforts in September 2025 to address these concerns are multifaceted, encompassing enforcement actions, import alerts, and public advisories. The FDA's "Green List" initiative, launched on September 05, 2025, is a significant step in this direction, aiming to proactively prevent the entry of potentially harmful substances.

While the FDA continues to approve novel drugs, including peptide-based therapeutics, as seen in the 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest where 46 novel drugs were approved, including one peptide, the September 2025 regulatory actions highlight a critical period of increased oversightBariatric Surgery and GLP-1 Drugs Both Support Sustained .... The FDA's actions serve as a crucial reminder that while peptide therapies hold immense promise, adherence to regulatory standards and rigorous safety protocols are paramount. The FDA's commitment to ensuring the safety and efficacy of all drug products, including those in the rapidly advancing field of peptide therapeutics, remains a top priorityExploring FDA-Approved Frontiers: Insights into Natural and .... The FDA's ongoing efforts, including those in 2025, are vital for maintaining public trust and safeguarding health.